(Q31159751)

29 June 2017

0 references

Impact of fesoterodine on quality of life: pooled data from two randomized trials (English)

1 reference

29 June 2017

1 reference

Con J Kelleher

1

1 reference

29 June 2017

Andrea Tubaro

series ordinal

2

1 reference

29 June 2017

Joseph T Wang

series ordinal

3

1 reference

29 June 2017

Zoe Kopp

series ordinal

4

1 reference

29 June 2017

1 July 2008

1 reference

29 June 2017

1 reference

29 June 2017

102

1 reference

29 June 2017

1

1 reference

29 June 2017

56-61

1 reference

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

29 June 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

The impact on health‐related quality of life of stress, urge and mixed urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

Minimal clinically important change in urinary incontinence detected by a quality of life assessment tool in overactive bladder syndrome with urge incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

Improved quality of life in patients with overactive bladder symptoms treated with solifenacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

Fesoterodine dose response in subjects with overactive bladder syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07710.X

10.1111/J.1464-410X.2008.07710.X

21 January 2018

Identifiers

DOI

1 reference

29 June 2017

1 reference